Sun Pharmaceutical Industries Limited today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical

Harbour BioMed a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology,

Finding easy-to-understand information about pediatric liver diseases that even kids can relate to has been a challenge, that's why the American Liver Foundation is launching a new pediatric liver

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech start-ups and ventures.

The pioneer of innovative proteomic and glycomic research solutions, today announced the acquisitions of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling

The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the electrophysiologic effects of ketamine on healthy brain function.

ArisGlobal , the leading provider of life sciences software that automates the core functions of drug development with its end-to-end LifeSphere® LifeSphere® technology platform, today announced

NATCO Pharma Limited announces launch of Pomalidomide Capsules in Canada, the first generic alternative to POMALYST® brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration

AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the UK